Population Screening Market Size, Share & Analysis Report, 2023-2032
The global population screening market size was exhibited at USD 25.27 billion in 2022 and is projected to hit around USD 43.87 billion by 2032, growing at a CAGR of 5.67% during the forecast period 2023 to 2032.
Key Pointers:
Population Screening Market Report Scope
|
Report Coverage |
Details |
|
Market Size in 2023 |
USD 26.7 Billion |
|
Market Size by 2032 |
USD 43.87 Billion |
|
Growth Rate from 2023 to 2032 |
CAGR of 5.67% |
|
Base year |
2022 |
|
Forecast period |
2023 to 2032 |
|
Segments covered |
Product, Business, gender, Type, Age |
|
Regional scope |
North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
|
Key companies profiled |
Agilent Technologies, Inc., Thermo Fisher Scientific, Inc., QIAGEN, F. Hoffmann-La Roche Ltd., Quest Diagnostics, Illumina, Inc., ARUP Laboratories, Novogene Co., Ltd., LGC Limited, Gene by Gene, Ltd. |
The growth of the market is attributed to the increasing prevalence of diseases, the growing geriatric population, and increasing investment in population screening tests. Moreover, the market is expected to be driven significantly by increasing technological advancements and developments in these tests.
An increase in the prevalence of cardiovascular diseases is expected to boost segment growth. According to the WHO, 17.7 million people die annually due to cardiovascular diseases, which is 32.0% of the total deaths occurring worldwide. Cardiovascular diseases are the leading cause of mortality and morbidity in the U.S. They are among the main causes of death globally, and hypertension & its pathological adverse effects pose a significant risk for other cardiac diseases, such as heart failure & stroke. There are multiple screening programs available for material fibrillation globally that aim to reduce the mortality rate. Identifying early-stage hypertension and other CVDs is of high significance in predicting & preventing major mortality & morbidity related to these diseases.
The growing prevalence of rare genetic diseases such as Spinal Muscular Atrophy (SMA) disorders and increased spending on population screening are among the major factors for the dominance of the market. According to the National Organization for Rare Disorders (NORD), SMA affects almost one in 10,000 people globally. In addition, according to SMA Canada, approximately 700 people were living with this condition in Canada as of July 2022. For instance, the CDC released the Recommended Uniform Screening Panel (RUSP) to states under its statewide universal newborn programs for the early identification of children with SMA. Thus, such initiatives are undertaken by governments to screen the population, thereby supporting the growth of the population screening market.
Players in the market adopt the strategy of product launches to strengthen their product portfolio and offer diverse, technologically advanced, & innovative population screening products to patients. Several market players engage in mergers & acquisitions to strengthen their market position. This strategy enables companies to boost their capabilities, expand product portfolios, and improve competencies. For instance, in August 2022, Thermo Fisher Scientific, Inc., launched an HIV-1 genotyping kit to identify the genetic mutations that resist Antiretroviral Therapeutics (ART). This kit was intended only for research purposes.
Population Screening Market Segmentation
| By Product | By Business | By Gender | By Type | By Age |
|
|
|
|
|
Chapter 1 Methodology and Scope
1.1 Market Segmentation
1.1.1 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Secondary Sources
1.3.3 Primary Research
1.3.4 Details Of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach 1: Commodity Flow Approach
1.6.1.2 Approach 2: Country-wise market estimation using bottom-up approach
1.7 Global Market: CAGR Calculation
1.8 Research Assumptions
1.9 List of Secondary Sources
1.10 List of Primary Sources
1.11 Objectives
1.11.1 Objective 1
1.11.2 Objective 2
1.12 List of Abbreviations
Chapter 2 Executive Summary
2.1 Market Snapshot
2.2 Segment Snapshot
2.3 Competitive Landscape Snapshot
Chapter 3 Popular Screening Market Variables, Trends & Scope
3.1 Population Screening Market Lineage Outlook
3.1.1 Parent Market Outlook
3.1.1.1 Cellular Health Screening Market Outlook
3.1.1.2 In Vitro Diagnostics Market Outlook
3.2 Penetration and Growth Prospect Mapping
3.3 Market Driver Analysis
3.3.1 Increasing Prevalence Of Diseases
3.3.2 Growing Investments In Population Screening
3.3.3 Growing Geriatric Population
3.4 Market Restraint Analysis
3.4.1 High Cost Associated With Screening
3.4.2 Psychological Factors, Knowledge, Attitudes, And Beliefs
3.5 SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
3.6 Porter’s Five Forces Analysis
3.7 Regulatory Framework
Chapter 4 Population Screening Market - Segment Analysis, by Geography, 2020 - 2032
4.1 Definition and Scope
4.2 Population Screening Market: Geography Movement Analysis
4.2.1 Nation
4.2.1.1 Nation Market Estimates And Forecast, 2020 - 2032
4.2.2 State
4.2.2.1 State market estimates and forecast, 2020 - 2032
Chapter 5 Population Screening Market - Segment Analysis, by Product, 2020 - 2032
5.1 Population Screening Market: Product Movement Analysis
5.1.1 Hardware Equipment (Instrument, Kits, Chips)
5.1.1.1 Hardware Equipment (Instrument, Kits, Chips) Market Estimates And Forecast, 2020 - 2032
5.1.2 Testing/Lab (Services)
5.1.2.1 Testing/Lab (Services) Market Estimates And Forecast, 2020 - 2032
5.1.3 Analytics/Interpretation (Personalization And Interpretation)
5.1.3.1 Analytics/Interpretation (Personalisation and interpretation) market estimates and forecast, 2020 - 2032
Chapter 6 Population Screening Market - Segment Analysis, by Business, 2020 - 2032
6.1 Definition and Scope
6.2 Population Screening Market: Business Movement Analysis
6.2.1 Hospitals
6.2.1.1 Hospitals Market Estimates And Forecast, 2020 - 2032
6.2.2 Research Institutes
6.2.2.1 Research Institutes Market Estimates And Forecast, 2020 - 2032
6.2.3 Diagnostic Labs
6.2.3.1 Diagnostic labs market estimates and forecast, 2020 - 2032
Chapter 7 Population Screening Market - Segment Analysis, by Gender, 2020 - 2032
7.1 Definition and Scope
7.2 Population Screening Market: Gender Movement Analysis
7.2.1 Male
7.2.1.1 Male Market Estimates And Forecast, 2020 - 2032
7.2.2 Female
7.2.2.1 Female market estimates and forecast, 2020 - 2032
Chapter 8 Population Screening Market - Segment Analysis, by Type, 2020 - 2032
8.1 Definition and Scope
8.2 Population Screening Market: Type Movement Analysis
8.2.1 Mass
8.2.1.1 Mass Market Estimates And Forecast, 2020 - 2032
8.2.2 Premium
8.2.2.1 Premium market estimates and forecast, 2020 - 2032
Chapter 9 Population Screening Market - Segment Analysis, by Age, 2020 - 2032
9.1 Definition and Scope
9.2 Population Screening Market: Age Movement Analysis
9.2.1 Age <15
9.2.1.1 Age <15 Market Estimates And Forecast, 2020 - 2032
9.2.2 15-65
9.2.2.1 15-65 Market Estimates And Forecast, 2020 - 2032
9.2.3 Ages 65+
9.2.3.1 Ages 65+ market estimates and forecast, 2020 - 2032
Chapter 10 Regional Business Analysis
10.1 Definition & Scope
10.2 Regional Market Share Analysis, 2023 & 2032
10.3 Regional Market Dashboard
10.4 Regional Market Snapshot
10.5 SWOT Analysis, By Factor (Political & Legal, Economic And Technological)
10.5.1 North America
10.5.2 Europe
10.5.3 Asia Pacific
10.5.4 Latin America
10.5.5 MEA
10.6 Market Size, & Forecasts, Trend Analysis, 2023 to 2032
10.7 North America
10.7.1 North America Market Estimates And Forecast, 2020 - 2032
10.7.2 U.S.
10.7.2.1 U.S. Population Screening Market, 2020 - 2032
10.7.2.2 Key country Dynamics
10.7.2.3 Regulatory Framework
10.7.2.4 Competitive Scenario
10.7.2.5 Recent Developments
10.7.2.6 Investments Scenario
10.7.3 Canada
10.7.3.1 Canada Population Screening Market, 2020 - 2032
10.7.3.2 Key country Dynamics
10.7.3.3 Regulatory Framework
10.7.3.4 Competitive Scenario
10.7.3.5 Recent Developments
10.7.3.6 Investments Scenario
10.8 Europe
10.8.1 Europe Population Screening Market, 2020 - 2032
10.8.2 UK
10.8.2.1 UK Population Screening Market, 2020 - 2032
10.8.2.2 Key country Dynamics
10.8.2.3 Regulatory Framework
10.8.2.4 Competitive Scenario
10.8.2.5 Recent Developments
10.8.2.6 Investments Scenario
10.8.3 Germany
10.8.3.1 Germany Population Screening Market, 2020 - 2032
10.8.3.2 Key country Dynamics
10.8.3.3 Regulatory Framework
10.8.3.4 Competitive Scenario
10.8.3.5 Recent Developments
10.8.3.6 Investments Scenario
10.8.4 Spain
10.8.4.1 Spain Population Screening Market, 2020 - 2032
10.8.4.2 Key country Dynamics
10.8.4.3 Regulatory Framework
10.8.4.4 Competitive Scenario
10.8.4.5 Recent Developments
10.8.4.6 Investments Scenario
10.8.5 France
10.8.5.1 France Population Screening Market, 2020 - 2032
10.8.5.2 Key country Dynamics
10.8.5.3 Regulatory Framework
10.8.5.4 Competitive Scenario
10.8.5.5 Recent Developments
10.8.5.6 Investments Scenario
10.8.6 Italy
10.8.6.1 Italy Population Screening Market, 2020 - 2032
10.8.6.2 Key country Dynamics
10.8.6.3 Regulatory Framework
10.8.6.4 Competitive Scenario
10.8.6.5 Recent Developments
10.8.6.6 Investments Scenario
10.8.7 Denmark
10.8.7.1 Denmark Population Screening Market, 2020 - 2032
10.8.7.2 Key country Dynamics
10.8.7.3 Regulatory Framework
10.8.7.4 Competitive Scenario
10.8.7.5 Recent Developments
10.8.7.6 Investments Scenario
10.8.8 Sweden
10.8.8.1 Sweden Population Screening Market, 2020 - 2032
10.8.8.2 Key country Dynamics
10.8.8.3 Regulatory Framework
10.8.8.4 Competitive Scenario
10.8.8.5 Recent Developments
10.8.8.6 Investments Scenario
10.8.9 Norway
10.8.9.1 Norway Population Screening Market, 2020 - 2032
10.8.9.2 Key country Dynamics
10.8.9.3 Regulatory Framework
10.8.9.4 Competitive Scenario
10.8.9.5 Recent Developments
10.8.9.6 Investments Scenario
10.9 Asia Pacific
10.9.1 Asia-Pacific Population Screening Market, 2020 - 2032
10.9.2 Japan
10.9.2.1 Japan Population Screening Market, 2020 - 2032
10.9.2.2 Key Country Dynamics
10.9.2.3 Regulatory Framework
10.9.2.4 Competitive Scenario
10.9.2.5 Recent Developments
10.9.2.6 Investments Scenario
10.9.3 China
10.9.3.1 China Population Screening Market, 2020 - 2032
10.9.3.2 Key Country Dynamics
10.9.3.3 Regulatory Framework
10.9.3.4 Competitive Scenario
10.9.3.5 Recent Developments
10.9.3.6 Investments Scenario
10.9.4 India
10.9.4.1 India Population Screening Market, 2020 - 2032
10.9.4.2 Key Country Dynamics
10.9.4.3 Regulatory Framework
10.9.4.4 Competitive Scenario
10.9.4.5 Recent Developments
10.9.4.6 Investments Scenario
10.9.5 South Korea
10.9.5.1 South Korea Population Screening Market, 2020 - 2032
10.9.5.2 Key Country Dynamics
10.9.5.3 Regulatory Framework
10.9.5.4 Competitive Scenario
10.9.5.5 Recent Developments
10.9.5.6 Investments Scenario
10.9.6 Thailand
10.9.6.1 Thailand Population Screening Market, 2020 - 2032
10.9.6.2 Key Country Dynamics
10.9.6.3 Regulatory Framework
10.9.6.4 Competitive Scenario
10.9.6.5 Recent Developments
10.9.6.6 Investments Scenario
10.9.7 Australia
10.9.7.1 Australia Population Screening Market, 2020 - 2032
10.9.7.2 Key country Dynamics
10.9.7.3 Regulatory Framework
10.9.7.4 Competitive Scenario
10.9.7.5 Recent Developments
10.9.7.6 Investments Scenario
10.10 Latin America
10.10.1 Latin America Population Screening Market, 2020 - 2032
10.10.2 Brazil
10.10.2.1 Brazil Population Screening Market, 2020 - 2032
10.10.2.2 Key Country Dynamics
10.10.2.3 Regulatory Framework
10.10.2.4 Competitive Scenario
10.10.2.5 Recent Developments
10.10.2.6 Investments Scenario
10.10.3 Mexico
10.10.3.1 Mexico Population Screening Market, 2020 - 2032
10.10.3.2 Key Country Dynamics
10.10.3.3 Regulatory Framework
10.10.3.4 Competitive Scenario
10.10.3.5 Recent Developments
10.10.3.6 Investments Scenario
10.10.4 Argentina
10.10.4.1 Argentina Population Screening Market, 2020 - 2032
10.10.4.2 Key Country Dynamics
10.10.4.3 Regulatory Framework
10.10.4.4 Competitive Scenario
10.10.4.5 Recent Developments
10.10.4.6 Investments Scenario
10.11 MEA
10.11.1 Mea Population Screening Market, 2020 - 2032
10.11.2 South Africa
10.11.2.1 South Africa Population Screening Market, 2020 - 2032
10.11.2.2 Key Country Dynamics
10.11.2.3 Regulatory Framework
10.11.2.4 Competitive Scenario
10.11.2.5 Recent Developments
10.11.2.6 Investments Scenario
10.11.3 Saudi Arabia
10.11.3.1 Saudi Arabia Population Screening Market, 2020 - 2032
10.11.3.2 Key Country Dynamics
10.11.3.3 Regulatory Framework
10.11.3.4 Competitive Scenario
10.11.3.5 Recent Developments
10.11.3.6 Investments Scenario
10.11.4 UAE
10.11.4.1 Uae Population Screening Market, 2020 - 2032
10.11.4.2 Key Country Dynamics
10.11.4.3 Regulatory Framework
10.11.4.4 Competitive Scenario
10.11.4.5 Recent Developments
10.11.4.6 Investments Scenario
10.11.5 Kuwait
10.11.5.1 Kuwait Population Screening Market, 2020 - 2032
10.11.5.2 Key country Dynamics
10.11.5.3 Regulatory Framework
10.11.5.4 Competitive Scenario
10.11.5.5 Recent Developments
10.11.5.6 Investments Scenario
Chapter 11 Competitive Analysis
11.1 Company/Competition Categorization (Key Innovators, Market leaders, Emerging Players)
11.2 Strategy Framework
11.3 Market Participation Categorization
11.4 Recent Developments & Impact Analysis, by Key Market Participants
11.5 Company Position Analysis
11.6 List of Distributors
11.6.1 Key Customers
11.6.2 Public Companies
11.6.3 Private Companies
11.7 Case Studies
11.7.1 Cost Analysis Of Cvd Patients With Screening Vs No Screening
11.7.2 Case Study: Population Health Screening
11.7.3 Case Study: Screening Of Raw Cases Samples Using The Agilent Quickprobe Gc/Ms System
11.7.4 Case Study: Evaluate The Performance Of Roche Cobas 4800 Hpv Test For Evaluating Hpv Tests For Screening
11.7.5 Case Study: Measurement Of Glucose And Hemoglobin In Diabetes
Chapter 12 COMPANY PROFILES
12.1 Company Profiles
12.1.1 AGILENT TECHNOLOGIES, INC.
12.1.1.1 Company Overview
12.1.1.2 Financial Performance
12.1.1.3 Product Benchmarking
12.1.1.4 Strategic Initiatives
12.1.2 THERMO FISHER SCIENTIFIC, INC.
12.1.2.1 Company Overview
12.1.2.2 Financial performance
12.1.2.3 Product Benchmarking
12.1.2.4 Strategic Initiatives
12.1.3 QIAGEN
12.1.3.1 Company Overview
12.1.3.2 Financial performance
12.1.3.3 Product Benchmarking
12.1.3.4 Strategic Initiatives
12.1.4 F. HOFFMANN-LA ROCHE LTD
12.1.4.1 Company Overview
12.1.4.2 Financial performance
12.1.4.3 Product Benchmarking
12.1.4.4 Strategic Initiatives
12.1.5 QUEST DIAGNOSTICS
12.1.5.1 Company Overview
12.1.5.2 Financial performance
12.1.5.3 Product Benchmarking
12.1.5.4 Strategic Initiatives
12.1.6 ILLUMINA, INC
12.1.6.1 Company Overview
12.1.6.2 Financial performance
12.1.6.3 Product Benchmarking
12.1.6.4 Strategic Initiatives
12.1.7 ARUP LABORATORIES
12.1.7.1 Company Overview
12.1.7.2 Product Benchmarking
12.1.7.3 Strategic Initiatives
12.1.8 NOVOGENE CO., LTD.
12.1.8.1 Company Overview
12.1.8.2 Product Benchmarking
12.1.8.3 Strategic Initiatives
12.1.9 LGC LIMITED
12.1.9.1 Company Overview
12.1.9.2 Product Benchmarking
12.1.9.3 Strategic Initiatives
12.1.10 GENE BY GENE, LTD.
12.1.10.1 Company Overview
12.1.10.2 Product Benchmarking
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers